Immunocore’s Brenetafusp: A Promising Study in PRAME-Positive Cancers

Immunocore Holdings Plc ((IMCR)) announced an update on their ongoing clinical study.

Study Overview: The clinical study titled ‘Phase 1/2 Study of IMC-F106C in Advance PRAME-Positive Cancers’ aims to evaluate the safety and efficacy of brenetafusp, an immune-mobilizing monoclonal T cell receptor against cancer (ImmTAC ®), in treating advanced solid tumors that are PRAME-positive. The study is significant as it explores a novel approach to target specific cancer markers, potentially offering new treatment options for patients with these types of cancers.

Intervention/Treatment: The study tests brenetafusp both as a single agent and in combination with other treatments. Brenetafusp is designed to mobilize the immune system against PRAME-positive cancer cells. It is administered alone or alongside checkpoint inhibitors, chemotherapy, targeted therapies, and multimodal therapies to assess its effectiveness and safety.

Study Design: This interventional study is non-randomized and follows a sequential intervention model. It is open-label, meaning there is no masking, and its primary purpose is treatment. The study is structured to systematically evaluate the effects of brenetafusp in different therapeutic combinations.

Study Timeline: The study began on January 30, 2020, with its latest update submitted on July 22, 2025. These dates are crucial as they indicate the study’s progression and ongoing commitment to evaluating brenetafusp’s potential benefits.

Market Implications: The ongoing study could significantly impact Immunocore Holdings Plc’s stock performance by potentially validating a new cancer treatment. Positive results might boost investor confidence and position the company favorably against competitors in the oncology sector, particularly those focusing on targeted cancer therapies.

The study is ongoing, with further details available on the ClinicalTrials portal.